NCT03583086View on ClinicalTrials.gov

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 10, 2018

Primary Completion Date

February 21, 2024

Study Completion Date

April 27, 2024

Conditions
Thymic CarcinomaNon-small Cell Lung CancerRefractory Thoracic TumorsSmall-Cell Lung Cancer
Interventions
DRUG

Vorolanib

Given by mouth

BIOLOGICAL

Nivolumab

Given by IV

Trial Locations (7)

19111

Fox Chase Cancer Center, Philadelphia

30322

Winship Cancer Institute, Emory University, Atlanta

37232

Vanderbilt-Ingram Cancer Center, Nashville

38120

Baptist Clinical Research Institute, Memphis

60637

University of Chicago Medical Center, Chicago

94304

Stanford Cancer Institute, Palo Alto

97213

Providence Cancer Institute Franz Clinic, Portland

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Xcovery Holdings, Inc.

INDUSTRY

lead

Vanderbilt-Ingram Cancer Center

OTHER